Androgen deprivation therapy (ADT) is one of the most effective treatments for advanced or high-risk prostate cancer. By dropping testosterone to castrate levels, ADT slows or stops the growth of androgen-sensitive tumor cells. That mechanism, ?however, is not selective. The same hormonal change that pressures the cancer also affects the heart, the bones, the metabolic system, the brain, and sexual function.
Understanding the side-effect profile is not about scaring patients away from a treatment that saves lives. It is about giving men and their families a clear picture so that monitoring, lifestyle changes, and supportive therapies can be put in place from day one. Most ADT side effects can be reduced with planning. Almost none can be reduced with surprise.
This article focuses on the side effects and long-term risks of ADT, not on indications, drug class comparisons, or duration decisions, which are determined by the treating oncologist based on the disease stage and risk category.
Cardiovascular and metabolic risk
This is the most clinically consequential category of ADT-related side effects.
- Multiple observational studies and meta-analyses report increased risks of myocardial infarction, stroke, sudden cardiac death, and certain arrhythmias in men on ADT, particularly those with pre-existing cardiovascular disease.
- ADT also commonly worsens metabolic risk factors: weight gain (especially central adiposity), insulin resistance, dyslipidemia (typically rising triglycerides and total cholesterol), and new-onset or worsening type 2 diabetes.
- The American Heart Association has issued a statement acknowledging the association between ADT and adverse cardiovascular events.
The clinical implication is straightforward. A man starting ADT should have a baseline cardiovascular assessment, and his clinician should know about prior cardiac disease, hypertension, diabetes, and lipid status. Optimizing those risk factors before starting ADT — and continuing surveillance during therapy — is the most evidence-based protective step.
Bone loss and fracture risk
ADT lowers bone mineral density at a measurable rate within the first year of therapy. Long-term ADT is associated with a higher risk of osteoporotic fractures.
ASCO guidance (2020) recommends, for men on ADT who are at increased fracture risk, the preferential use of denosumab, with bisphosphonates as an alternative, alongside calcium and vitamin D as appropriate. A baseline DEXA scan and periodic follow-up imaging help quantify the rate of bone loss and identify men who need pharmacologic protection.
For most men on long-term ADT, three steps belong on the care plan:
- Baseline DEXA before starting therapy.
- Adequate calcium and vitamin D, with deficiency corrected.
- Resistance and weight-bearing exercise.
For men with existing osteoporosis, prior fragility fracture, or other elevated fracture risk, anti-resorptive therapy (denosumab or a bisphosphonate) should be considered. This is a clinical decision based on individual risk.
Hot flashes and vasomotor symptoms
Hot flashes are among the most common ADT side effects. Reports across studies place the prevalence above 70–80%, often beginning within weeks of starting therapy. They are not dangerous but can substantially affect sleep, mood, and quality of life.
Several interventions have evidence for symptom reduction:
- Lifestyle measures (layered clothing, room cooling, avoiding triggers).
- Selective serotonin reuptake inhibitors (SSRIs) such as venlafaxine.
- Gabapentin in some patients.
- Cyproterone acetate in selected cases (where regulatory approval and clinical context permit).
Hormone-based hot flash treatments commonly used in menopause are generally not appropriate for men on ADT for prostate cancer.
Sexual function: libido, erectile function, and identity
ADT lowers libido in nearly all men and frequently produces erectile dysfunction independent of any local treatment effects (radiation or surgery). Penile shrinkage and reduced ejaculate are also reported.
Honest pre-treatment counseling matters here. So does access to:
- PDE5 inhibitors and non-pharmacologic ED therapies, if locally appropriate.
- Couples counseling and sexual-health support.
- Psychiatric support for body-image and identity concerns, which are real and under-discussed in this population.
Mood, fatigue, and cognition
ADT is associated with increased rates of depressive symptoms, fatigue, and subjective cognitive decline. The literature on objective cognitive impairment is more mixed, but the clinical signal is real enough that screening for depression and fatigue belongs in routine ADT follow-up.
Supervised and home-based exercise programs have the strongest evidence for reducing ADT-related fatigue, metabolic side effects, and at least some aspects of cognitive dysfunction. Exercise is not optional supportive care for ADT — it is a core part of the treatment plan.
Body composition: muscle loss, weight gain
ADT causes loss of lean mass and gain of fat mass, often in the same year. The pattern increases sarcopenic-obesity risk, which feeds into cardiometabolic and fall-and-fracture risk above. Resistance training is the highest-yield countermeasure. Adequate protein intake (commonly targeted around 1.2–1.6 g/kg of target body weight per day, with attention to renal function) supports the response.
Other effects to know
- Anemia. Mild normocytic anemia is common; severe anemia is uncommon.
- Gynecomastia and breast tenderness. More frequent with antiandrogen monotherapy than LHRH-based regimens; can be managed with prophylactic radiotherapy or, in some settings, tamoxifen.
- Liver function changes. Periodic monitoring is part of standard ADT follow-up.
Strategies to reduce overall risk
The contemporary picture of ADT is not “tolerate the side effects.” It is “minimize exposure and actively manage the side effects.” NCCN and ASCO have moved in this direction with several recommendations:
- Use intermittent ADT in selected patients, where evidence supports non-inferiority compared with continuous ADT.
- Limit duration of therapy to what the disease state requires.
- Optimize cardiovascular risk factors before and during therapy.
- Address bone health proactively with calcium, vitamin D, exercise, and anti-resorptive therapy when indicated.
- Build exercise into the prescription, not as advice but as a structured part of the plan.
Bottom line
ADT remains a powerful and often necessary therapy for advanced prostate cancer. It also has a real and predictable side-effect profile across cardiovascular, bone, sexual, cognitive, and metabolic systems. The men who do best on ADT are not the ones who got “lucky” with side effects. They are the ones whose care plan started addressing those side effects before the first injection.
Side-effect management deserves the same rigor and the same evidence base as the cancer treatment itself.
References
- Bhindi B, Zhang B, Lee H, et al. Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management. ASCO Educational Book 2024. https://ascopubs.org/doi/10.1200/EDBK_433126
- Saylor PJ, Smith MR. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer. Circulation 2015. https://www.ahajournals.org/doi/10.1161/circulationaha.115.012519
- Saad F, Brown JE, Van Poznak C, et al. Bone Health Issues for Men With Prostate Cancer Receiving Androgen Deprivation Therapy: ASCO Guideline. J Clin Oncol 2020.
- Bressi B, et al. Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood. Medicina 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10819522/
- National Comprehensive Cancer Network (NCCN). ADT: Minimizing Exposure and Mitigating Side Effects. https://education.nccn.org/node/2399
- Sexual Medicine Society of North America. Common Side Effects of ADT for Prostate Cancer. https://smsna.org/patients/blog/common-side-effects-of-androgen-deprivation-therapy-adt-for-prostate-cancer
